Clinical trials: PD-L1
Carcinoma, Non-Small-Cell Lung
A Study of Atezolizumab Compared With Docetaxel in Non-Small Cell Lung Cancer (NSCLC) After Failure With Platinum-Containing Chemotherapy
This Phase III, multicenter, open-label, randomized, controlled study is designed to evaluate the efficacy and safety of the anti-programmed death-ligand 1 (PD-L1) antibody atezolizumab compared with docetaxel in participants…
- Trial name
- IMpower210 (NCT02813785)
- Testing
- Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody, Docetaxel
- Where
- 38 sites in China, Malaysia and 3 more
- Volunteers
- 565 people
- Sponsor
- Hoffmann-La Roche
Urothelial Carcinoma
Atezolizumab With Bevacizumab in Previously Untreated Metastatic/Unresectable Urothelial Cancer
This is a phase II study assessing the activity of bevacizumab combined with atezolizumab in metastatic urothelial carcinoma patients who are ineligible for cisplatin-based therapy.
- Trial name
- NCT03272217
- Testing
- Atezolizumab, Bevacizumab
- Where
- 8 sites in United States
- Volunteers
- 16 people
- Sponsor
- Arjun Balar, MD
Rectal Cancer
Avelumab With Chemoradiation in Locally Advanced Rectal Cancer
This trial is investigating the inclusion of avelumab post long-course chemo-radiotherapy in patients with resectable locally advanced rectal cancer.
- Trial name
- NCT03299660
- Testing
- Avelumab, 5 Fluorouracil, Capecitabine Pill
- Where
- 7 sites in Australia
- Volunteers
- 37 people
- Sponsor
- Peter MacCallum Cancer Centre, Australia
Small Cell Lung Cancer (SCLC)
A Study of Pembrolizumab (MK-3475) in Combination With Etoposide/Platinum (Cisplatin or Carboplatin) for Participants With Extensive Stage Small Cell Lung Cancer (MK-3475-604/KEYNOTE-604)
The purpose of this study is to assess the safety and efficacy of pembrolizumab plus standard of care (SOC) chemotherapy (etoposide/platinum [EP]) in participants with newly diagnosed extensive stage small cell lung cancer…
- Trial name
- NCT03066778
- Testing
- Pembrolizumab, Normal saline solution, Carboplatin
- Where
- 148 sites in United States, Australia and 17 more
- Volunteers
- 453 people
- Sponsor
- Merck Sharp & Dohme LLC
Breast Cancer
Addition of PD-L1 Antibody MEDI4736 to a Taxane-anthracycline Chemotherapy in Triple Negative Breast Cancer
To date no targeted agents are available to treat TNBC. Therefore chemotherapy is the only treatment option. TNBC often has a high amount of tumour infiltrating lymphocytes.
- Trial name
- GeparNuevo (NCT02685059)
- Testing
- MEDI4736 (Anti PD-L1), nab-Paclitaxel, Epirubicin
- Where
- Germany
- Volunteers
- 174 people
- Sponsor
- GBG Forschungs GmbH
Metastatic Breast Cancer
Induction Therapy of PTX+BV Followed by Atezolizumab+Nab-PTX for PD-L1+ TNBC
The objective of this research is to evaluate the efficacy of the treatment strategy to administer atezolizumab + nab-paclitaxel (PTX) following 2 cycles of induction therapy with PTX + bevacizumab (induction treatment strategy)…
- Trial name
- INDUCE (NCT06793553)
- Testing
- Induction therapy
- Where
- Japan
- Volunteers
- 106 people
- Sponsor
- Japan Breast Cancer Research Group
NSCLC
A Study to Evaluate Pembrolizumab Plus Lenvatinib in PD-L1 Positive TKI Resistant NSCLC Patients
This study will investigate the efficacy and safety of the combination of pembrolizumab and lenvatinib in PD-L1 positive patients with TKI-resistant EGFR-mutated advanced NSCLC.
- Trial name
- NCT05078931
- Testing
- Pembrolizumab, Lenvatinib
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Shanghai Chest Hospital
Carcinoma, Non-Small-Cell Lung
Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)
The purpose of this study is to compare pembrolizumab (MK-3475) in combination with sacituzumab govitecan with pembrolizumab alone with respect to progression-free survival (PFS) and overall survival (OS) per Response Evaluation…
- Trial name
- NCT05609968
- Testing
- Sacituzumab Govitecan, Pembrolizumab
- Where
- 180 sites in United States, Australia and 23 more
- Volunteers
- 614 people
- Sponsor
- Merck Sharp & Dohme LLC
Advanced Solid Tumor, Advanced Malignant Neoplasm
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C…
- Conditions
- Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer, Metastatic Solid Tumor
- Trial name
- NCT04585750
- Testing
- rezatapopt, pembrolizumab
- Where
- 76 sites in United States, Australia and 7 more
- Volunteers
- 300 people
- Sponsor
- PMV Pharmaceuticals, Inc
Neoplasms, Colorectal Neoplasms
Study of MK-1697 in Participants With Advanced Solid Tumors (MK-1697-001)
The purpose of this study is to evaluate the safety and preliminary efficacy of MK-1697. There are 2 parts in this study: dose escalation to determine the recommended phase 2 dose (RP2D) and confirm the RP2D (Part A) and cohort…
- Conditions
- Neoplasms, Colorectal Neoplasms, Head and Neck Neoplasms
- Trial name
- NCT03515824
- Testing
- MK-1697
- Where
- 2 sites in Australia, Hong Kong
- Volunteers
- 22 people
- Sponsor
- Merck Sharp & Dohme LLC
Non Small Cell Lung Cancer
A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)
The study is being conducted to to explore the reasonable dosage and evaluate the efficacy, safety and tolerability of HLX43 (Anti-PD-L1 ADC) in Patients with Advanced Non-small Cell Lung Cancer (NSCLC)
- Trial name
- NCT06907615
- Testing
- HLX43 DOSE 1 (2.0 mg/kg), HLX43 DOSE 2 (2.5 mg/kg)
- Where
- 2 sites in United States, China
- Volunteers
- 243 people
- Sponsor
- Shanghai Henlius Biotech
Advanced Malignant Neoplasm
A Study to Evaluate the Efficacy and Safety of QLF31907 Combination Therapy in Patients With Advanced Malignant Tumors
This study is designed to evaluate the safety and efficacy of QLF31907 combination therapy in advanced malignant tumors.
- Trial name
- NCT06394713
- Testing
- QLF31907, Irinotecan, Docetaxel
- Volunteers
- 60 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Solid Tumor, Unresectable or Metastatic Melanoma
PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors
To obtain evidence of antitumor effect of CX-072 in combination with anticancer therapy in adult patients with solid tumor based upon overall response rate by Response Evaluation Criteria in Solid Tumors (RECIST)
- Trial name
- NCT03993379
- Testing
- CX-072, Ipilimumab
- Where
- 27 sites in United States, Australia and 3 more
- Volunteers
- 3 people
- Sponsor
- CytomX Therapeutics
NPC
IBI310 in Combination With Siltilimab in Subjects With Anti-PD-1/PD-L1 Resistance R/M NPC
This is a phase 1b/II, open label, multicenter study of IBI310 (Anti-CTLA4 mAb) in combination with Sintilimab in patients with recurrent/metastatic Nasopharyngeal Carcinoma that failed prior Anti-PD-1/PD-L1 therapy
- Trial name
- NCT04945421
- Testing
- Sintilimab, IBI310
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Metastatic Non-Small Lung Cell Cancer, Recurrent Non-Small Lung Cell Cancer
Phase 2 DoceRamPem for Patients With Metastatic or Recurrent NSCLC Who Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade
This phase 2 trial will evaluate the safety and efficacy of combining immunotherapy with a PD-1 checkpoint inhibitor (Pembrolizumab), an anti-VEGF receptor (Ramucirumab), and a taxane chemotherapy (Docetaxel) in treating patients…
- Conditions
- Metastatic Non-Small Lung Cell Cancer, Recurrent Non-Small Lung Cell Cancer, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8
- Trial name
- DoceRamPem (NCT04340882)
- Testing
- Docetaxel, Pembrolizumab, Ramucirumab
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Emory University
NSCLC Stage IV, Brain Metastases
Cranial Radiotherapy Plus Chemoimmunotherapy in Untreated Driver-mutation Negative NSCLC With Stable Brain Metastasis
Non-small cell lung cancer (NSCLC), the most prevalent form of lung cancer, has a significant risk of brain metastasis (BM). Historically, the median overall survival for advanced NSCLC patients with BM was under six months with…
- Trial name
- NCT06501391
- Testing
- PD-L1/PD-1 inhibitor and chemotherapy, SRT or WBRT
- Where
- China
- Volunteers
- 54 people
- Sponsor
- Fudan University
Advanced Sarcoma, Metastatic Sarcoma
YH001 Plus Envafolimab With or Without Doxorubicin in Patients With Advanced or Metastatic Sarcoma
This is a multicenter, open label, Phase 1/2 study of YH001 initially given in combination with envafolimab, and then given in combination with envafolimab plus doxorubicin in patients with advanced or metastatic sarcoma…
- Conditions
- Advanced Sarcoma, Metastatic Sarcoma, Soft Tissue Sarcoma
- Trial name
- NCT05448820
- Testing
- YH001, Envafolimab, Doxorubicin
- Where
- 6 sites in United States
- Volunteers
- 15 people
- Sponsor
- Tracon Pharmaceuticals Inc.
Stage IV NSCLC
Harnessing Allo-immunity to Enhance Immune Checkpoint Inhibitor Responses in Advanced NSCLC
Veterans with advanced lung cancer may benefit from recent advances in technologies that is designed to change the activities of their own white blood cells and help kill tumors.
- Trial name
- HAITEN-ICI (NCT06064279)
- Testing
- Poly ICLC, IVIG
- Where
- United States
- Sponsor
- VA Office of Research and Development
Non-small Cell Lung Cancer
An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer
This is an open-label, multicenter, non-randomized, Phase 2 study to determine the safety, tolerability and efficacy of encorafenib given in combination with binimetinib in patients with BRAFV600E-mutant metastatic non-small cell…
- Trial name
- NCT03915951
- Testing
- encorafenib, binimetinib
- Where
- 143 sites in United States, Italy and 3 more
- Volunteers
- 98 people
- Sponsor
- Pfizer
Castration Resistant Prostate Cancer
N-803 Alone or in Combination With BN-Brachyury Vaccine or Bintrafusp Alfa (M7824) for Participants With Castration Resistant Prostate Cancer
Background: Prostate cancer does not trigger a strong immune response in the body. Hormone therapy, to reduce levels of testosterone in the body, can be helpful to treat some prostate cancers.
- Trial name
- NCT05445882
- Testing
- Bintrafusp alfa, N-803, BN-Brachyury
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.